Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioAlliance and TopoTarget merge

Executive Summary

Publicly held cancer companies TopoTarget AS and BioAlliance Pharma SA entered into a merger agreement that will culminate with TopoTarget operating as a wholly owned BioAlliance subsidiary, owning approximately 1/3 of the combined entity’s stock. For every 27 shares held, TopoTarget stockholders get two BioAlliance shares. Based on the pre-announcement market average, the deal is worth €83.4mm ($115mm).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies